Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

Table 1

Baseline characteristics of patients administered tenofovir (TDF) or entecavir (ETV).

	ETV ()	TDF ()
Age, years	35.1 ± 4.5	33.7 ± 4.6	0.28
Gender, male	74.2% (49/66)	76.7% (23/30)	1.00
Height (cm)	167.09 ± 7.22	164.93 ± 7.45	0.19
Weight (kg)	62.58 ± 10.43	58.37 ± 7.98	0.05
History of alcohol use	21.2% (14/66)	26.7% (8/30)	0.61
History of smoking	19.7% (13/66)	26.7% (8/30)	0.44
Family history of Hepatitis B	71.2% (47/66)	70.0% (21/30)	1.00
Pretreatment HBV-DNA,  IU/mL	7.33 ± 0.79	7.25 ± 0.83	0.62
Pretreatment serum ALT, U/L	154.59 ± 122.05	168.53 ± 112.39	0.60
Elevated serum ALT before therapy	93.9% (62/66)	96.7% (29/30)	0.58

IU/mL, international unit per milliliter; U/L, unit per liter; ALT, alanine aminotransferase.